Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... 2015 American Process Inc. (Atlanta, ... TN) recently signed a joint agreement ... resins using nanocellulose, a rapidly emerging high performance, ... is the limited number of feedstock materials available. ... to printed parts for load bearing applications. ...
    (Date:5/27/2015)... , May 27, 2015 RXi ... company focused on discovering and developing innovative therapies ... today announced that it has commenced a public offering ... purchase shares of its common stock and overallotment ... stock. The shares of common stock, warrants and ...
    (Date:5/27/2015)... , May 27, 2015 /CNW/ - CQDM, Brain ... close to $8.5M to six (6) multi-disciplinary and multi-provincial ... neuroscience within their Focus on Brain strategic initiative. To ... entities involved as in-kind contributions. This exciting announcement was ... Association for Neuroscience in the presence of Inez Jabalpurwala, ...
    (Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
    Breaking Biology Technology:American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3
    ... ... Now Available on goBalto.com , ... San Francisco, CA (PRWEB) August 24, 2009 -- goBalto, an online drug ... Clinical Trials Support is making its proprietary list of over 950 Latin ...
    ... 21 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: SCR ... supplier,of branded generic and innovative pharmaceuticals in China, today ... in China,s Essential,Drug List ("EDL"), which was issued by ... In the 2009 second quarter ...
    ... tree magnet commemorating your last vacation is programmed for ... Similarly, semiconductors are programmed to convey bits of information ... cell phone. Scientists are working to coax those ... some functions like magnets, such as data recording and ...
    Cached Biology Technology:goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites 2goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites 3Forty-two of Simcere's Generic Drugs Enter China's Essential Drug List 2Let there be light: Teaching magnets to do more than just stick around 2Let there be light: Teaching magnets to do more than just stick around 3
    (Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
    (Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
    (Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
    Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
    ... Edmonton, Alberta, Canada Sept. 7, 2011: Not all ... change in nutrition labels in North America to reflect this, ... According to a scientific review published in the latest ... produced by ruminant animals such as dairy and beef cattle ...
    ... ,CHICAGO -- Researchers at Northwestern University Feinberg School ... with rheumatoid arthritis become hyperactive and attack the joints and ... protein that keeps them in line the same way a ... The Feinberg School team has identified this bouncer, ...
    ... team of leading marine scientists from around the world ... the deep sea, the Earth,s largest ecosystem. Instead, ... consumers., In a comprehensive analysis published online this week ... fisheries biologists, economists, mathematicians and international policy experts show ...
    Cached Biology News:Time to reboot thinking on trans fats -- natural trans fats from dairy and beef are good 2New 'bouncer' molecule halts rheumatoid arthritis 2Deep-sea fish in deep trouble 2Deep-sea fish in deep trouble 3
    ...
    ... Optimization Kits without ammonium sulfate are compatible ... such as Taq and AmpliThem™™ DNA polymerases. ... PCR systems in one experiment by adding ... into the PreMixes supplied with the kit. ...
    ... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
    Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
    Biology Products: